PURPOSE: To investigate associations between imaging features and mutational status of clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS: This multi-institutional, multi-reader study included 103 patients (77 men; median age 59 years, range 34-79) with ccRCC examined with CT in 81 patients, MRI in 19, and both CT and MRI in three; images were downloaded from The Cancer Imaging Archive, an NCI-funded project for genome-mapping and analyses. Imaging features [size (mm), margin (well-defined or ill-defined), composition (solid or cystic), necrosis (for solid tumors: 0%, 1%-33%, 34%-66% or >66%), growth pattern (endophytic, <50% exophytic, or ≥50% exophytic), and calcification (present, absent, or indeterminate)] were reviewed independently by three readers blinded to mutational data. The association of imaging features with mutational status (VHL, BAP1, PBRM1, SETD2, KDM5C, and MUC4) was assessed. RESULTS: Median tumor size was 49 mm (range 14-162 mm), 73 (71%) tumors had well-defined margins, 98 (95%) tumors were solid, 95 (92%) showed presence of necrosis, 46 (45%) had ≥50% exophytic component, and 18 (19.8%) had calcification. VHL (n = 52) and PBRM1 (n = 24) were the most common mutations. BAP1 mutation was associated with ill-defined margin and presence of calcification (p = 0.02 and 0.002, respectively, Pearson's χ (2) test); MUC4 mutation was associated with an exophytic growth pattern (p = 0.002, Mann-Whitney U test). CONCLUSIONS: BAP1 mutation was associated with ill-defined tumor margins and presence of calcification; MUC4 mutation was associated with exophytic growth. Given the known prognostic implications of BAP1 and MUC4 mutations, these results support using radiogenomics to aid in prognostication and management.
PURPOSE: To investigate associations between imaging features and mutational status of clear cell renal cell carcinoma (ccRCC). MATERIALS AND METHODS: This multi-institutional, multi-reader study included 103 patients (77 men; median age 59 years, range 34-79) with ccRCC examined with CT in 81 patients, MRI in 19, and both CT and MRI in three; images were downloaded from The Cancer Imaging Archive, an NCI-funded project for genome-mapping and analyses. Imaging features [size (mm), margin (well-defined or ill-defined), composition (solid or cystic), necrosis (for solid tumors: 0%, 1%-33%, 34%-66% or >66%), growth pattern (endophytic, <50% exophytic, or ≥50% exophytic), and calcification (present, absent, or indeterminate)] were reviewed independently by three readers blinded to mutational data. The association of imaging features with mutational status (VHL, BAP1, PBRM1, SETD2, KDM5C, and MUC4) was assessed. RESULTS: Median tumor size was 49 mm (range 14-162 mm), 73 (71%) tumors had well-defined margins, 98 (95%) tumors were solid, 95 (92%) showed presence of necrosis, 46 (45%) had ≥50% exophytic component, and 18 (19.8%) had calcification. VHL (n = 52) and PBRM1 (n = 24) were the most common mutations. BAP1 mutation was associated with ill-defined margin and presence of calcification (p = 0.02 and 0.002, respectively, Pearson's χ (2) test); MUC4 mutation was associated with an exophytic growth pattern (p = 0.002, Mann-Whitney U test). CONCLUSIONS:BAP1 mutation was associated with ill-defined tumor margins and presence of calcification; MUC4 mutation was associated with exophytic growth. Given the known prognostic implications of BAP1 and MUC4 mutations, these results support using radiogenomics to aid in prognostication and management.
Authors: Gerben Duns; Eva van den Berg; Inge van Duivenbode; Jan Osinga; Harry Hollema; Robert M W Hofstra; Klaas Kok Journal: Cancer Res Date: 2010-05-25 Impact factor: 12.701
Authors: Ramakrishna Venkatesh; Kyle Weld; Caroline D Ames; Sherbourne R Figenshau; Chandru P Sundaram; Gerald L Andriole; Ralph V Clayman; Jaime Landman Journal: Urology Date: 2006-06 Impact factor: 2.649
Authors: T Shuin; K Kondo; S Torigoe; T Kishida; Y Kubota; M Hosaka; Y Nagashima; H Kitamura; F Latif; B Zbar Journal: Cancer Res Date: 1994-06-01 Impact factor: 12.701
Authors: Ignacio Varela; Patrick Tarpey; Keiran Raine; Dachuan Huang; Choon Kiat Ong; Philip Stephens; Helen Davies; David Jones; Meng-Lay Lin; Jon Teague; Graham Bignell; Adam Butler; Juok Cho; Gillian L Dalgliesh; Danushka Galappaththige; Chris Greenman; Claire Hardy; Mingming Jia; Calli Latimer; King Wai Lau; John Marshall; Stuart McLaren; Andrew Menzies; Laura Mudie; Lucy Stebbings; David A Largaespada; L F A Wessels; Stephane Richard; Richard J Kahnoski; John Anema; David A Tuveson; Pedro A Perez-Mancera; Ville Mustonen; Andrej Fischer; David J Adams; Alistair Rust; Waraporn Chan-on; Chutima Subimerb; Karl Dykema; Kyle Furge; Peter J Campbell; Bin Tean Teh; Michael R Stratton; P Andrew Futreal Journal: Nature Date: 2011-01-19 Impact factor: 49.962
Authors: Alexander Sankin; Abraham A Hakimi; Nina Mikkilineni; Irina Ostrovnaya; Mikhail T Silk; Yupu Liang; Roy Mano; Michael Chevinsky; Robert J Motzer; Stephen B Solomon; Emily H Cheng; Jeremy C Durack; Jonathan A Coleman; Paul Russo; James J Hsieh Journal: Cancer Med Date: 2014-08-14 Impact factor: 4.452
Authors: Gillian L Dalgliesh; Kyle Furge; Chris Greenman; Lina Chen; Graham Bignell; Adam Butler; Helen Davies; Sarah Edkins; Claire Hardy; Calli Latimer; Jon Teague; Jenny Andrews; Syd Barthorpe; Dave Beare; Gemma Buck; Peter J Campbell; Simon Forbes; Mingming Jia; David Jones; Henry Knott; Chai Yin Kok; King Wai Lau; Catherine Leroy; Meng-Lay Lin; David J McBride; Mark Maddison; Simon Maguire; Kirsten McLay; Andrew Menzies; Tatiana Mironenko; Lee Mulderrig; Laura Mudie; Sarah O'Meara; Erin Pleasance; Arjunan Rajasingham; Rebecca Shepherd; Raffaella Smith; Lucy Stebbings; Philip Stephens; Gurpreet Tang; Patrick S Tarpey; Kelly Turrell; Karl J Dykema; Sok Kean Khoo; David Petillo; Bill Wondergem; John Anema; Richard J Kahnoski; Bin Tean Teh; Michael R Stratton; P Andrew Futreal Journal: Nature Date: 2010-01-06 Impact factor: 49.962
Authors: Nicholas J Farber; Christopher J Kim; Parth K Modi; Jane D Hon; Evita T Sadimin; Eric A Singer Journal: Transl Cancer Res Date: 2017-06 Impact factor: 1.241
Authors: Q Yin; S-C Hung; W K Rathmell; L Shen; L Wang; W Lin; J R Fielding; A H Khandani; M E Woods; M I Milowsky; S A Brooks; E M Wallen; D Shen Journal: Clin Radiol Date: 2018-05-23 Impact factor: 2.350
Authors: Matthew S Davenport; Hersh Chandarana; Nicole E Curci; Ankur Doshi; Samuel D Kaffenberger; Ivan Pedrosa; Erick M Remer; Nicola Schieda; Atul B Shinagare; Andrew D Smith; Zhen J Wang; Shane A Wells; Stuart G Silverman Journal: Abdom Radiol (NY) Date: 2018-09
Authors: Radka Stoyanova; Mandeep Takhar; Yohann Tschudi; John C Ford; Gabriel Solórzano; Nicholas Erho; Yoganand Balagurunathan; Sanoj Punnen; Elai Davicioni; Robert J Gillies; Alan Pollack Journal: Transl Cancer Res Date: 2016-08 Impact factor: 1.241
Authors: Harrison X Bai; Ashley M Lee; Li Yang; Paul Zhang; Christos Davatzikos; John M Maris; Sharon J Diskin Journal: Br J Radiol Date: 2016-02-11 Impact factor: 3.039
Authors: Heike E Daldrup-Link; Christina Sammet; Marta Hernanz-Schulman; Katherine A Barsness; Anne Marie Cahill; Ellen Chung; Andrea S Doria; Kassa Darge; Rajesh Krishnamurthy; Matthew P Lungren; Sheila Moore; Laura Olivieri; Ashok Panigrahy; Alexander J Towbin; Andrew Trout; Stephan Voss Journal: J Am Coll Radiol Date: 2016-02-02 Impact factor: 5.532